Clofazimine Alternatives Compared
| Clofazimine | Dapsone | Rifampin |
|
|---|
| Clofazimine | Dapsone | Rifampin |
|
|||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Prescribed for Leprosy - Dapsone-Sensitive, Leprosy, Leprosy - Erythema Nodosum Leprosum, Leprosy - Dapsone-Resistant. Clofazimine may also be used for purposes not listed in this medication guide. |
Prescription only
Prescribed for Dermatitis Herpetiformis, Bullous Pemphigoid, Leprosy - Lepromatous, Leprosy, Leprosy - Tuberculoid, Leukocytoclastic Vasculitis, Linear IgA Disease, Pemphigoid, Pemphigus... View more |
Prescription only
Prescribed for Bartonellosis, Endocarditis, Legionella Pneumonia, Haemophilus influenzae Prophylaxis, Leprosy, Leprosy - Borderline, Leprosy - Tuberculoid, Meningitis, Meningococcal Disease... View more |
Related suggestions Leprosy
|
|||||||||||||||
| More about Clofazimine | More about Dapsone | More about Rifampin | ||||||||||||||||
| Ratings & Reviews | ||||||||||||||||||
|
Be the first to share your experience with this drug. |
Dapsone has an average rating of 7.4 out of 10 from a total of 26 ratings on Drugs.com. 64% of reviewers reported a positive effect, while 24% reported a negative effect. |
Rifampin has an average rating of 6.2 out of 10 from a total of 21 ratings on Drugs.com. 42% of reviewers reported a positive effect, while 21% reported a negative effect. |
||||||||||||||||
| Drug Class | ||||||||||||||||||
| Side Effects | ||||||||||||||||||
| Generic Availability | ||||||||||||||||||
|
N/A |
Lower cost generic |
Lower cost generic |
||||||||||||||||
| Pricing and Coupons * Prices are without insurance | ||||||||||||||||||
|
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
View all Dapsone prices |
View all Rifampin prices |
||||||||||||||||
| Dosage Forms Available | ||||||||||||||||||
|
N/A |
|
|
||||||||||||||||
| Brand Names | ||||||||||||||||||
|
N/A |
N/A |
Rifadin, Rifadin IV, Rimactane | ||||||||||||||||
| Half Life The half-life of a drug is the time taken for the plasma concentration of a drug to reduce to half its original value. | ||||||||||||||||||
|
1680 hours |
50 hours |
4 hours |
||||||||||||||||
| CSA Schedule ** View glossary of terms | ||||||||||||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||
| Pregnancy Category | ||||||||||||||||||
|
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
||||||||||||||||
| Drug Interactions | ||||||||||||||||||
|
A total of 307 drugs are known to interact with Clofazimine:
|
A total of 246 drugs are known to interact with Dapsone:
|
A total of 737 drugs are known to interact with Rifampin:
|
||||||||||||||||
| Alcohol/Food/Lifestyle Interactions | ||||||||||||||||||
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
|
||||||||||||||||
| Disease Interactions | ||||||||||||||||||
| First Approval Date | ||||||||||||||||||
|
N/A |
July 03, 1979 |
May 21, 1971 |
||||||||||||||||
| WADA Class View World Anti-Doping Agency classifications. | ||||||||||||||||||
|
N/A |
N/A |
N/A |
||||||||||||||||
| More Information | ||||||||||||||||||
| Patient resources | ||||||||||||||||||
| Professional Resources | ||||||||||||||||||
| Related Treatment Guide | ||||||||||||||||||
|
||||||||||||||||||
** The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.